SUPPLEMENTAL MATERIAL
SUPPLEMENTARY TABLE 1. Summary of the key clinical outcomes of different radiotracers currently used in the clinical setting or under research for palliative
treatment of bone metastases.1-6
Radiotracer
%bone uptake
Main elimination route
Response to therapy (%)
Duration of therapeutic response (months)
Side effects
85
Urinary
50-87
2-7
Significant
SrCl2
55
Urinary
65-90
3-6
Significant
Y-EDTMP
45-50
Urinary
--
--
--
Sn-DTPA
77
Urinary
60-83
4-5
Mild
153
Sm-EDTMP
65
Urinary
55-83
2-3
Moderate
166
Ho-DOTMP
16-54
Urinary
NE
NE
Moderate
Tm-EDTMP
50-55
Urinary
--
--
--
70
Urinary
NE
NE
Mild
54-80
Urinary
55-80
NE
Mild
32
P-ortofosfato
89
90
117m
170
177
Lu-DOTMP
177
Lu-EDTMP
186
Re-HEDP
55
Urinary
55-85
2-4
Mild
188
Re-HEDP
30
Urinary
64-77
3-6
Mild
223
41
Intestinal
58-75
2-3
Moderate
RaCl2
Legend: NE – not established.
Note: Data for 90Y-EDTMP and 170Tm-EDTMP is preclinical.
1
REFERENCES:
1.
International Atomic Energy Agency, Radiation Biology: A Handbook for Teachers and
Students, Training Course Series 42, Vienna, 2010
2.
Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med. 2005;46 Suppl 1(1):38S47S.
3.
Silberstein EB. Teletherapy and radiopharmaceutical therapy of painful bone metastases. Semin
Nucl Med 2005, 35(2): 152-8.
4.
Nilsson S, Strang P, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study
of radium-223 chloride for the palliation of painful bone metastases in patients with castrationresistant prostate cancer. Eur J Cancer. 2012; 48(5):678-86.
5.
Saeed S, Zaknun J, Jameel G, et al.
177
Lu-EDTMP - A bone pain palliating agent:
Biodistribution and skeletal uptake in osseous metastatic patients. J Nuc Med. 2011:52 (Supp
1):1750
6.
Yuan J, Liu C, Liu X, et al. Efficacy and safety of
177
Lu-EDTMP in bone metastatic pain
palliation in breast cancer and hormone refractory prostate cancer: a phase II study. Clin Nuc
Med. 2013: 38(2):88-92
2